Home
Trials
For Patients
Sponsors
About Us
Contact Us
ImmuPharma/Orion (IPP-201101)
1-Active/Enrolling
A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus
Sign Up
TRIALS STATUS
1-Active/Enrolling
(3)
2-Ongoing/In Follow Up
(6)
3-Closed
(21)
USEFUL LINKS
ClinicalTrials.gov
CenterWatch.com
U.S. Food and Drug Administration